Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates.
We describe the experience of a single medical centre with continuous factor VIII (FVIII) infusion therapy in a cohort of patients undergoing elective surgery. Twenty-eight patients had a total of 45 procedures. Intraoperative haemostasis was considered excellent in all 45 cases. FVIII levels were maintained between 46% and 191% of normal (median, 103%) for 2-7 days. Bleeding occurred after five procedures (11%) at times when factor VIII levels were within haemostatic range. No patient required reoperation to control bleeding. There were no cases of sepsis related to continuous infusion of factor VIII. We conclude that continuous infusion: (1) is a safe and effective means of replacement therapy in patients with haemophilia undergoing surgery; (2) provides easier monitoring and more constant coagulation factor levels; and (3) has the potential to decrease the cost of replacement therapy by reducing overall usage of product.
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
D
D
Dingli
D A
DA
Gastineau
G S
GS
Gilchrist
W L
WL
Nichols
J L
JL
Wilke
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005169:Factor VIII / Q000008:administration & dosage* / Q000032:analysis; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D006488:Hemostasis, Surgical / Q000379:methods*; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000517:prevention & control / Q000628:therapy; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies
D011994:Recombinant Proteins; C078147:F8 protein, human; D005169:Factor VIII